1. Allen, L. M Creaven, P.J: Comparison of the human pharmacokinetics of VM 26 and VP16, two antineoplastic epipodophyllotoxin glucopyrano- side derivatives. Eur. J. Cancer 11, 697–707 (1975).
2. Allen, L. M., Mareks, C., Creaven, P. J: 4’Demethyl-epipodophyllic acid-9-(4,6-ethylidene-/?-D-glucopyranoside), the major urinary metabolite of VP 16-213 in man. Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 17, 6 (1976).
3. Allen, L. M., Shirley, M: Mechanism of cellular transport of two epi-podophyllotoxin glucopyranoside derivatives, VM 26 (VM) and VP16 (VP). Proc. Am. Ass. Cancer Res. & Am. Soc. clin. Oncol. 18, 22 (1977).
4. Allen, L. M: Comparison of uptake and binding of two epipodophyllo- toxinglucopyranosides, 4’-demethyl epipodophyllotoxin thenylidene-ß-D- glucoside and 4’-demethyl epipodophyllotoxin ethylidene-ß-D-glucoside, in the L1210 leukemia cell. Cancer Res.38, 2549–2554 (1978).
5. Arnold, A. M: Podophyllotoxin derivate VP 16-213. Cancer Chemother. Pharmacol. 3, 71–80 (1979).